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Abstract  
Introduction: Gonadal steroid hormones play a crucial role during skeletal growth and maturation in both men and women. The aim of this study 
is to evaluate the relationship of sex hormone levels, bone mineral density and biochemical markers of bone turnover in healthy Moroccan men. 
Methods: 142 Moroccan men who had no previous diagnosis of osteoporosis were enrolled prospectively in this cross-sectional study between 
December 2009 and August 2010. Also, subjects were excluded from the study if they had conditions affecting bone metabolism. Different 
biochemical parameters were assayed: Testosterone, Estradiol, sex hormone binding globulin, Osteocalcin, vitamin D, crosslaps, intact parathyroid 
hormone and alkaline phosphatase. Dual-energy X-ray absorptiometry was used to measure the Bone mineral density (BMD) (g/cm2). Results: In 
this study, among the 142 Moroccan men, 29 (20.1%) had densitometry osteoporosis and the prevalence of vitamin D insufficiency was 94%. No 
correlation was found between Estradiol, Testosterone and bone mineral density but we found significant differences in the levels of Estradiol 
between patients with osteoporosis, osteopenia and normal patients. Bone mineral density at the lumbar spine was negatively correlated to 
hormone-binding globulin and positively correlated to free androgen index, free estrogen index and the Body mass index. BMD at the total hip was 
positively correlated to free androgen index, Body mass index and negatively correlated to sex hormone binding globulin, alkaline phosphatase, 
intact parathyroid hormone, osteocalcin, Crosslaps and age. Conclusion: Our study showed that increasing age, intact parathyroid hormone and 
alkaline phosphatase levels and decreasing body mass index were the most important independent factors associated to the presence of a low 
BMD at the total hip. Increasing body mass index and free androgen index level were the most important independent factors associated to the 
presence of a low BMD at the lumbar spine. The combination of variable that best predicted the male osteoporosis is age, body mass index, 
alkaline phosphatase and cigarette smoking.  
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Osteoporosis is a metabolic bone disorder characterized by low bone 
mass and micro- architectural deterioration, with a subsequent 
increase in bone fragility and susceptibility to fracture [1]. It affects 
13% of Caucasian men older than 50 years (versus 40% in women) 
and a 15% lifetime risk of osteoporotic fractures in the same age 
group [2]. Gonadal steroid hormones play a crucial role during 
skeletal growth and maturation in both men and women [3]. In fact, 
hypogonadism is a well recognized risk factor for osteoporosis in 
aging men, and it is found in 10% to 15% of cases [4, 5]. Also, 
most cohort studies indicate that estrogen concentrations are 
associated with bone mineral density (BMD) and bone turnover as 
well as bone loss in aging men [4, 5]. This correlation between 
Estradiol (E) and bone remodeling markers has been proven by 
treatment of elderly men with an aromatase inhibitor resulted in 
significant increase in bone resorption, together with decreases in 
bone formation markers [6, 7] . Sex hormone-binding globulin 
(SHBG) is a plasma glycoprotein that binds to sex steroids, thereby 
regulating their bioavailability [8], and the link between SHBG, BMD 
and bone remodeling markers should be given a careful attention. 
Also, vitamin D (25(OH)D3 ) has been measured, because 
25(OH)D3 deficiency includes secondary hyperparathyroidism, 
accelerated bone loss, increased bone turnover, osteoporosis and 
fractures. The aim of this study was to evaluate the relationship 
between sex hormone levels, biochemical markers of bone turnover 







This was a cross-sectional study conducted from December 2009 to 
August 2010. Men were recruited prospectively through 
advertisements and "word of mouth". Men who volunteered to 
participate in the study were enrolled after taking an informed and 
written consent. One hundred and forty two consecutive men who 
had no previous diagnosis of osteoporosis took part in the study; all 
subjects were screened using a detailed questionnaire, history, 
behaviors and physical examination. Subjects were excluded from 
the study if they had conditions affecting bone metabolism, such as 
diseases of kidney, liver, parathyroid, thyroid, diabetes mellitus, 
hyperprolactinemia, rheumatoid arthritis, ankylosing spondylitis, 
malabsorption syndromes, malignant tumors, hematologic diseases, 
or previous pathological fractures. Subjects were also excluded if 
they had been receiving corticosteroids, thyroid hormone, fluoride, 
bisphosphonate, calcitonin, thiazide diuretics, barbiturates, 
antiseizure medications, 25(OH)D3 or calcium-containing drugs. Our 
institutional review board approved this study. The procedures of 
the study were in accordance with the Declaration of Helsinki, and 
local ethics committee approval was obtained for the study. Each 
subject completed a standardized questionnaire designed to 
document putative risk factors of osteoporosis. Height and weight 
were measured in our rheumatology center before DXA 
measurement, in light indoor clothes without shoes. Body mass 
index (BMI) was calculated by dividing weight in kilograms by height 
in meters squared.  
  
BMD measurement  
  
Bone mineral density was determined by a Lunar Prodigy Vision DXA 
system (Lunar Corp., Madison, WI). The DXA scans were obtained 
by standard procedures supplied by the manufacturer for scanning 
and analysis. All BMD measurements were carried out by 2 
experienced technicians. Daily quality control was carried out by 
measurement of a lunar phantom. At the time of the study, 
phantom measurements showed stable results. The phantom 
precision expressed as the coefficient of variation percentage was 
0.08 %. Moreover, reproducibility has been assessed by the same 2 
technicians in clinical practice and showed a smallest detectable 
difference of 0.04 g/cm2 (spine) and 0.02 (hips). Patient BMD was 
measured at the lumbar spine and at the femurs (i.e., femoral neck 
and total hip).  
  
Biological measurements  
  
All subjects had fasting blood taken in the morning. The samples 
were frozen and stored at -20°C and subsequently thawed and 
analyzed in one batch. Serum Testosterone (T), Estradiol (E), 
Vitamin D (25(OH)D3) sex hormone binding globulin (SHBG), 
Osteocalcin (OC), and Crosslaps (β-CTX), intact parathyroid 
hormone (PTHi) were measured using electrochimiluminescence 
immunoassay (ECLIA) technique (Cobas e601, Roche Diagnostics 
GmBH, Mannheim,Germany). Alkaline phosphatase (ALP) was 
measured by (Dimension® RxL Max® Integrated Chemistry System 
of Siemens). All the laboratory tests were subject to validation using 
National External Quality Assurance Schemes. The free androgen 
index (FAI), having been shown to be more sensitive for identifying 
subjects with abnormal androgen status than total or free 
testosterone. Free androgen index (FAI= Total testosterone/SHBG x 
100) was calculated from the ratio of serum T to SHBG to give an 
estimate of the free circulating concentration. Similarly, the free 
estradiol index (FEI= Total E/SHBG * 100) was calculated from the 
ratio of serum E to SHBG.  
  
Statistical analysis  
  
Results are presented as means (SD) and categorical variables are 
expressed as frequencies. To compare normal patients, patients 
with osteopenia and osteoporosis, chi-square test and ANOVA were 
used firstly. Correlations between continuous variables were 
calculated using Pearson correlation coefficients. Potential risk 
factors were entered to a stepwise conditional binary regression 
analysis and the resulted odds ratios with 95% confidence intervals 
were reported. Logistic-regression models were used to analyze the 
most important factors related to the presence of osteoporosis. The 
level for significance was taken as p ≤0.05. Excel 2007 and SPSS 





In this cohort of 142 men, the mean ± SD (range) age and Body 
mass index were 63.31±8.7 years and 26.42±4.20 kg/m2, 
respectively. Based on the diagnostic criteria of osteoporosis (T-
score below -2.5 at the lumbar spine, the femoral neck or the total 
hip site) 44 subjects were diagnosed as normal (30.99%), 69 as 
osteopenia (48.59%) and 29 as osteoporosis (20.42%). In all 
patients, in which we found low levels of 25(OH)D3 ( the mean ± SD 
(range)) were 20.47±6.15 ng/mL. In our study, the prevalence of 
smoking was 52.11 % and cigarette smoking was associated with a 
high prevalence of osteoporosis (p=0.004), and the smokers had a 
high level of ALP (p=0.029) and a low total hip BMD (TH_BMD) 
comparing to the nonsmokers (p=0.029) group. The concentrations 
of the biochemical parameters were compared among the three 
groups (normal bone mass group, osteopenia group and 
osteoporosis group). The comparison result showed that the plasma 
levels of ALP, SHBG, and OC were significantly higher in the 
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osteoporosis group than in the other groups, but the levels of the 
FAI were significantly lower in the osteoporosis group compared to 
the other groups (Table 1).  
  
Results of correlation analysis between bone mineral 
density with the biochemical parameters, BMI and age 
(Table 2)  
  
Pearson correlation analysis showed significant negative correlations 
between the total hip BMD and the following variables ALP, PTHi, 
OC, β-CTX, SHBG, FAI, Age and the BMI. And positive correlations 
with the following variables BMI , FAI. Pearson correlation analysis 
showed significant positive correlations between Lumbar spine BMD 
and the following parameters the FAI and the BMI. And a negative 
correlation was found with the SHBG.  
  
Results of correlation analysis between sexual hormones 
with blood biochemical parameters, BMD, BMI and age 
(Table 2)  
  
Pearson correlation analysis showed that there were positive 
correlations between estradiol and the following variables β-CTX, 
OC, PTHi, and there were negative correlations between estradiol 
and the following variables T, SHBG and vitamine D. There was a 
significant significant positive correlation between the T and the 
BMI. and a significant negative correlation was found with the BMI. 
There were significant negative correlations between the FAI and 
the age, and between the FEI and the age too.  
  
Results of correlation analysis between vitamin D with 
blood biochemical parameters, BMD, BMI and age (Table 2)  
  
There was a significant positive correlation between the 25(OH)D3 
and the following parameters E, T. A significant negative correlation 
was found with the lumbar spine BMD.  
  
Multiple regression analysis with bone mineral density as 
dependent variable (Table 3)  
  
Multiple regression analysis was therefore performed to determine 
the combination of variables that accounted for the greatest 
proportion of variance in BMD at each site. PTHi, alkaline 
phosphatase, age and Body mass index were related to total hip 
BMD. BMI and free androgen index were significantly related to 
Lumbar spine BMD.  
  
Multiple logistic regressions  
  
To determine the combination of variables that best predicted the 
male osteoporosis, a multiple logistic regression analysis was 
performed (Table 4) and the best model comprised ALP, Age, BMI 





We analyzed in this study the association between sex hormone 
levels, biochemical markers of bone turnover and BMD in healthy 
Moroccan men. We found a higher prevalence of osteoporosis 
(20.45%) than what was reported in the normal Moroccan 
population [9] , and among Caucasian men older than 50 years 
(13%) [2], which was probably due to a hazard effect and to the 
small number of men enrolled in this study. Our observations in 
terms of BMI are very similar to those of most studies showing that 
lower BMI scores were associated with BMD loss [9, 10]. The BMI of 
the osteoporosis group was slightly lower compared with those of 
the osteopenia and normal groups, and these differences were 
significant [11]. There were negative correlations between the BMI 
and OC, BMI and β-CTX, BMI and T, BMI and 25(OH)D3. Thus, high 
BMI was associated with low levels of bone remodeling markers, 
Testosterone and 25(OH)D3. Overweight may protect men against 
bone loss, several explanations have been proposed. First of them 
by increasing the amount of biologically available estrogens, in fact, 
estrogen is known to inhibit bone resorption by osteoclasts [12]. A 
larger body mass imposes a greater mechanical loading on bone 
and that bone mass increases to accommodate the greater load. 
Although smoking is often cited as a risk factor for osteoporosis, the 
influence of smoking on osteoporosis remains unclear. In our study 
the prevalence of smoking was 52.11 % and cigarette smoking is 
associated with a high prevalence of osteoporosis (p=0.004), and 
smokers had a high level of ALP (p=0.029) and a low TH_BMD 
comparing to nonsmokers (p=0.029). Pearson correlation analysis in 
the group of smokers showed that there were positive correlations 
between the contents of ALP and these parameters β-CTX, OC and 
PTHi. Thus, smoking was associated with high level of bone 
turnover markers.  
  
Smoking is thought to cause low bone density through a 
combination of different mechanisms, smoking has been linked to a 
decrease in parathyroid hormone and estrogen levels as well as to 
an increase in the level of cortisol and adrenal androgens, changes 
that have been linked to an increased risk of osteoporosis [13]. 
Smoking reduces body mass, which is postulated to provide an 
osteogenic stimulus and is linked to higher BMD [14]. Smoking 
reduces the level of 25(OH)D3 in the body [15]. Smoking increases 
free radicals and oxidative stress which affects bone resorption [16]. 
Smokers are more likely to suffer from peripheral vascular disease, 
reducing blood supply to the bones [17] . Finally, there may also 
exist direct toxic effects of many of the constituents in tobacco 
smoke on bone cells [18]. Smoking is significantly associated with 
higher level of alkaline phosphatase in men [19]. Thus, In our study 
smokers had a high level of ALP (p=0.029). We do not find any 
significant difference in E, T levels between patients in osteoporotic 
group, osteopenic group and normal group nor any correlation 
between blood E and BMD whatever the site measured. Slemenda 
and al found that BMD measurements at the hip and spine 
correlated negatively with serum T levels (correlation coefficients 
varying from -0.20 to -0.28, p= 0.03-0.10) [20]. "Legrand and al" 
and "Lomereau and al" did not show any statistical significant 
difference in E levels between controls and osteoporotic patients, 
and the blood E did not correlate with spine BMD [11, 21]. In 
contrast, several cross-sectional studies have shown a significant 
correlation between E levels and bone mass in men [5, 22-24]. FAI 
correlated positively to BMD but greater at the lumbar spine. FEI 
correlated weakly to the BMD at the lumbar spine. "Gennari and al" 
found that the free estradiol index (FEI) correlates positively with 
BMD values at the femur and lumbar spine [24]. Pearson correlation 
analysis showed that there were positive correlations between the 
contents of E and these parameters PTH, OC and β-CTX, but 
negative correlations between the FAI and age, FEI and age, BMI 
and OC, BMI and β-CTX, BMI and T. The association between E and 
bone resorption markers has been confirmed in another study 
where significant correlations were found only with markers of bone 
resorption (serum and urinary NTX), but not with biochemical 
indices of bone formation (OC), bone alkaline phosphatase 
isoenzyme (BAP) [25]. Moreover, prospective studies showed that 
serum E was a better predictor than serum T of both the increase in 
bone loss in elderly men [24, 26]. In a cross-sectional study that 
included men and women, "Khosla and al" reported inverse 
correlations between urinary NTX (cross-linked N-terminal 
telopeptides of type I collagen) levels and both "bioavailable" E and 
"bioavailable" T [12]. "Szulc and al"found that only bioavailable E 
levels in men were negatively correlated with bone turnover, but no 
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associations were observed with total E, or any testosterone 
measure [27].  
  
The impact of serum testosterone on bone health parameters 
appears less significant and uncertain [28]. The current evidence 
suggests that E plays a greater role in maintenance of skeletal 
health than testosterone, but that androgens also have direct 
beneficial effects on bone. Testosterone is metabolized via the 
cytochrome P450 aromatase enzyme complex into 17β-estradiol, 
and increasing evidence indicates that at least part of the effect of 
androgens on bone is mediated by their aromatization to estrogens 
[29, 30]. And the other effects of the androgens by androgen 
receptors are present on bone cells, and androgen receptor 
mediated actions on bone have been known for several years [31]. 
In our data SHBG was positively correlated to age and negatively 
correlated to BMI and BMD (lumbar spine and total hip). Thus, the 
concentration of SHBG rises with age and the levels of SHBG are 
low in obese patients and extremely high in patients with anorexia 
nervosa [31]. Our study and several case-control studies have 
demonstrated no difference in total sex steroids, but significantly 
higher SHBG and lower FAI in osteoporotic group [30-32]. "Legrand 
and al" observed higher levels of plasma SHBG in two thirds of the 
80 osteoporotic patients in their study. SHBG correlated negatively 
with BMD at the femoral neck, both in idiopathic osteoporosis (r = -
0.34, p <0.01) and secondary osteoporosis (r = -0.34, p < 0.01) 
[21]. Likewise, "Evans and al" found a significant increase in SHBG 
levels in 81 men with both idiopathic osteoporosis and fractures as 
compared with 68 healthy controls [31]. Longitudinal study shows 
that SHBG correlated negatively with trabecular bone mass [32].  
  
We defined the hypovitaminosis D as a circulating level of 25(OH)D3 
below 30 ng/mL. In this study, the prevalence of hypovitaminosis D 
was 94%, similar to results of previous studies of vitamin D 
prevalence in Moroccan women. Although Morocco enjoys a sunny 
climate throughout the year, many factors may explain these high 
prevalences. It may be related to low vitamin D intake and in our 
country, food is not supplemented with vitamin D. Hence, cutaneous 
synthesis would be the major source of 25(OH)D3. This high 
prevalence of hypovitaminosis D was also reported in a cross-
sectional study among Saudi Arabian men (87.8%) [33]. Also, we 
got significant positive correlation either between 25(OH)D3 levels 
and E ,T and the BMI. 25(OH)D3 was negatively correlated to age, 
hence, men with low 25(OH)D3 were older and with low level of T 
and E. A recent randomized placebo-controlled trial by "Pilz and al" 
suggested that 25(OH)D3 may increase the production of T in men 
[34]. "David M Lee and al" in a cross-sectional study of 3369 
community-dwelling men aged 40-79 years in eight European 
centers, 25(OH)D3 was positively associated with total and free T 
and negatively with E and LH in age- and centre-adjusted linear 
regressions, this result was in contrast to our finding for E [35]. We 
did not find any correlation between 25(OH)D3 and BMD, some 
studies found a positive relationship between serum 25(OH)D3 and 
BMD, but others did not find any relationship neither [36, 37]. 
Perhaps because of differing age, race, gender and 
health/nutritional status in this reported cohorts. In our data not all 
patients with vitamin D insufficiency (25(OH)D3 < 30 ng/l) develop 
secondary hyperparathyroidism but only 50%. In fact, vitamin D 
insufficiency and PTH over the 65 ng/l, this may be a threshold for 
initiating the optimal replacement therapy [38]. The TH_BMD 
correlate negatively with SHBG, OC, PTH, β-CTX, ALP, age and 
positively with FAI, BMI. The LS_BMD was negatively correlated to 
SHBG and positively correlated to FAI, FEI and the BMI. BMI was 
the best predictor of BMD at all sites. In fact, the relationship 
between markers of bone remodeling and BMD in men varies in the 
literature, it is usually weak [35, 36] but appears stronger in 
subjects over 50 years of age. Some authors do not find any 
significant relationship between such markers and BMD in men, 
whatever their age [39].  
  
Our study demonstrated that increasing age, PTHi and ALP levels 
and decreasing BMI were the most important independent factors 
associated with the presence of a low bone mineral density at the 
total hip. Increasing BMI and FAI level were the most important 
independent factors associated with the presence of a low bone 
mineral density at the lumbar spine. The best model that can 
predict osteoporosis in Moroccan men was the combination of the 
ALP, Age, BMI and cigarette smoking. Our study has strengths and 
limitations. All of the DXA and biochemical measurements were 
conducted with a single bone densitometer and a single 
biochemistry laboratory, with very careful quality controls in place. 
The main limitations lie in the cross-sectional nature of the study 
and in the procedures used to select subjects, who were all 
volunteers and ambulatory. The study population had a higher 






BMI was the best predictor of BMD at all sites. Age, PTHi, ALP and 
BMI were the best predictors at the TH_BMD and BMI, FAI were 
related to LS_BMD. The combination of variable that best predicted 
the male osteoporosis is Age, ALP, BMI and cigarette smoking. 94% 
of the patients in this study had a vitamin D insufficiency. 
Furthermore, a positive correlation was found between 25(OH)D3 
and E,T and negative correlation was found with the age. However, 
large scale longitudinal studies are needed to further evaluate the 
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Table 1: Comparison between normal patients, patients with 
osteopenia and osteoporosis (n=142)  
Table 2: Correlation between biochemical values and age, BMI and 
BMD (n=142)  
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Table 3: Multiple linear regression analysis with BMD as dependent 
variable (n=142)  
Table 4: Multiple logistic regression analysis with BMD as 
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Table 1: comparison between normal patients, patients with osteopenia and osteoporosis (n=142) 




Osteoporosis     
(n=29) 












65.48 (30.88) 59.11 
(21.73) 
82.57 (53.19) 0.007 0.005 NS NS 
ALP (U/L): 
m (SD) 
82.67 (21.13) 88.62 
(21.15) 






68.23 (34.75) 0.007 NS 0.006 NS 
T (ng/dL): 
m (SD) 




9.13 (3.24) 8.52 (3.2) 7.33 (3.83) NS NS 0.049 NS 
E (pg/mL): 
m (SD) 
22.83 (9.17) 21.33 
(11.08) 












20.01 (10.23) 24.15 
(22.53) 








1.232 (0.187) 0.989 
(0.115) 





1.07 (0.12) 0.89 (0.098) 0.699 (0.1) <0.001 <0.001 <0.001 <0.001 
Mean ± SD : m (SD)  *: <0.05  **: < 0.001 
One way analysis of variance + Tests Post hoc (Bonferroni)  
p: osteoporosis-osteopenia-normal    p1 :  osteoporosis – osteopenia  p2   : osteoporosis - normal 
 p3   osteopenia - normal 
LS_BMD  lumbar spine bone mineral density    TH_BMD  Total hip bone mineral density   FAI    Free 
androgen index   SHBG    Sex Hormones Binding Globulin  
FEI     Free estrogen index   ALP     Alkaline phosphatase PTHi    Parathormone (PTH) intact              OC   
Osteocalcin 














Page number not for citation purposes 8 
Table 2:  correlation between biochemical values and age, BMI and BMD (n=142) 
  ALP PTHi OC β-CTX E T SHBG FEI FAI 25(OH)D
3 
Age BMI 
PTHi 0.237+                       
OC 0.252+ 0.666++                     
β-CTX 0.310+
+ 
0.565++ 0.879++                   
E 0.110 0.283+ 0.257+ 0.234+                 
T 0.02 0.06 0.13 0.06 0.45++               
SHBG 0.09 0.15 0.10 0.12 0.224+ 0.562++             
FEI -0.04 0.07 0.07 0.02 0.557+
+ 
-0.13 - 0.53++           
FAI -0.10 -0.13 -0.003 -0.16 0.16 0.251++ - 
0.483++ 
0.567++         
25(OH)D
3 
-0.04 -0.07 0.10 0.09 0.192+ 0.190+ 0.07 0.08 0.12       




-0.13     
BMI -0.09 0.01 -0.173+ -0.211+ -0.12 -
0.339++ 
-0.253++ 0.13 0.05 -0.177+ -0.09   












+ : <0.05 
































Table 3: multiple linear regression analysis with BMD as dependent variable 
(n=142) 
TH_ BMD Bêta SE p-value 
BMI 0.334 0.003 <0.001 
ALP -0.218 <0.001 0.001 
PTHi -0.231 <0.001 0.002 
AGE -0.174 0.001 0.015 
LS _BMD Bêta SE p-value 
BMI 0.360 0.004 ˃0.001 
FAI 0.171 0.005 0.020 
Table 4: multiple logistic regression analysis 
with the presence of osteoporosis as dependent 
variable  (n=142) 




ALP 1.0255 [1.0062-1.0453] 0.0096 
Age 1.0807 [1.0172-1.1481] 0.0120 
BMI 0.8407 [0.7293-0.9691] 0.0167 
Cigarette 
smoking 
1.8557 [1.0488-3.2833] 0.0337 
